← All indications
Gliosarcoma
Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)
Drugs by status
Phase 3 trials (9)
Phase 2 trials (94)
- 131i-tm-601
- 2-fluoropropionyl-labeled pegylated dimeric rgd peptide
- sucrose
- plerixafor
- rilotumumab
- aminolevulinic acid
- anti-egfrviii car transduced pbl
- atezolizumab
- Silatecan
- sorafenib
- bendamustine
- binimetinib
- irinotecan
- carboxyamidotriazole
- lenalidomide
- temsirolimus
- cilengitide
- cixutumumab
- valproic acid
- dovitinib
- doxorubicin
- encorafenib
- enzastaurin
- erc1671
- n-(4-hydroxyphenyl)all-trans retinamide
- vismodegib
- paclitaxel
- imatinib
- lapatinib
- nintedanib
- +64 more
Phase 1 trials (62)
- phenobarbital
- azacitidine
- axitinib
- allogeneic natural killer cells
- amg-232
- bms-986016
- ridaforolimus
- mk-1775
- azurin-derived cell-penetrating peptide p28
- urea
- carboxylesterase-expressing allogeneic neural stem cells
- progesterone
- dimethyl fumarate
- selinexor
- e. coli cd-expressing genetically modified neural stem cells
- ef5
- flucytosine
- fosphenytoin
- carbamazepine
- leucovorin
- gadopenteate dimeglumine
- marizomib
- memantine
- methimazole
- alisertib
- montanide isa 720
- vitamin c
- hsv-1716
- dordaviprone
- panobinostat
- +32 more
Organizations
Organization Involved with Phase 3 Indications (12)
- Celldex Therapeutics
- National Cancer Institute (NCI)
- University of Washington
- NRG Oncology
- Radiation Therapy Oncology Group
- Southwest Oncology Group
- University of Lausanne
- University of Utah
- European Organisation for Research and Treatment of Cancer
- University of Texas at Houston
- University of Wisconsin
- Celilo Cancer Center at Mid-Columbia Medical Center
Organization Involved with Phase 2 Indications (81)
- AbbVie
- Eisai
- Celgene
- Millennium Pharmaceuticals
- Bristol-Myers Squibb
- Amgen
- OSI Pharmaceuticals
- Schering-Plough
- Merck
- Eli Lilly
- Genentech
- Pfizer
- Progenics
- Sanofi
- Novartis
- Arno Therapeutics
- Array BioPharma
- Axelar AB
- Bayer
- Center for Neurosciences, Tucson
- DNAtrix, Inc.
- GlaxoSmithKline
- Lantheus Medical Imaging
- Northwest Biotherapeutics
- NovoCure Ltd.
- TransMolecular
- Agenus Inc.
- Boehringer Ingelheim
- National Institutes of Health (NIH)
- Medical Research Council
- +51 more
Organization Involved with Phase 1 Indications (22)
- AstraZeneca
- Exelixis
- Genzyme
- Biogen
- Ariad Pharmaceuticals
- Mundipharma
- Oncoceutics, Inc.
- Pharmacia
- Cancer and Leukemia Group B (CALGB)
- University of Nebraska
- University of Toronto
- Virginia Commonwealth University
- University of Chicago
- Vanderbilt University
- SCRI Development Innovations
- City of Hope National Medical Center
- Keryx
- The Andrew McDonough B+ Foundation
- Musella Foundation
- University of Geneva
- Center Trials & Treatment Inc.
- Secura
Organization Involved with Other Experimental Indications (3)